Navigation Links
Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohn's Disease
Date:5/15/2013

PRINCETON, N.J., May 15, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.  The program has previously received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for oral BDP as a treatment for pediatric Crohn's Disease.

The objective of Study BDP-PCD-01, entitled "A Phase 1 Pharmacokinetic/Pharmacodynamic Study of Oral Beclomethasone 17,21-Dipropionate (BDP) in Healthy Adolescents and Young Adults", is to determine the pharmacokinetic (PK) and pharmacodynamic (PD) profile of oral BDP in healthy young male and female adolescents and adults. This study will enroll 24 subjects, with assessments to be completed in June 2013.

The program has been designed in collaboration with an expert in PK modeling and simulation, Jeffrey S. Barrett , PhD, FCP.  Dr. Barrett is Director of both the Laboratory for Applied PK/PD and also the Pediatric Pharmacology Research Unit at The Children's Hospital of Philadelphia. He is also Professor of Pediatrics at the University of Pennsylvania Medical School.

"There are currently no FDA approved corticosteroid therapies for pediatric Crohn's disease and we believe that SGX203 has the potential to meet an important medical need in children with this serious illness," stated Kevin J. Horgan , MD, Senior Vice President & Chief Medical Officer of Soligenix. "Data from this study will be used to refine the PK model we have established with Dr. Barrett.  The PK
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
2. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
3. Soligenix to Present at World Vaccine Congress & Expo
4. Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
5. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
6. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
7. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
8. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
9. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
10. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
11. Soligenix Reports Second Quarter 2012 Financial Results and Highlights Recent Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015 Research and ... the  "North America Portable X Ray Devices Market ...  report to their offering.       (Logo: ... market for Portable X-Ray Devices is ... 2014 to 2020 X-Ray is a ...
(Date:5/27/2015)... 27, 2015 The global vitreoretinal ... market with analysis and forecast of revenue. This market ... is estimated to grow at a CAGR of 8.9 ... the TOC of the global vitreoretinal surgery devices market ... provided. This report also provides a glimpse of the ...
(Date:5/27/2015)... 2015  Marcio Donatelli, a senior marketing associate with the animal health ... volunteer work in a healthcare setting in Bangkok, Thailand ... for people in need with respect and dignity is the guiding star ... -based Elanco employee in a LillyPad blog . Donatelli ... , Colombia , France , ...
Breaking Medicine Technology:North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3
... Md., May 16, 2011 Science, public health, and ... Drug Administration. Information in this document is designed for credentialed ... of May 16, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... any regulatory or enforcement actions due to legal limitations. ...
... RATON, Fla., May 16, 2011 Breckenridge Pharmaceutical, ... have reached an agreement with Takeda Pharmaceutical Company ... litigation related to Pioglitazone Hydrochloride 15 mg, 30 ... version of Actos®. Under the terms of the ...
Cached Medicine Technology:FDA News & Notes - Week of May 16, 2011 2FDA News & Notes - Week of May 16, 2011 3Breckenridge Pharmaceutical Announces Settlement of Actos® (Pioglitazone Hydrochloride) Patent Litigation 2
(Date:5/27/2015)... CA (PRWEB) May 27, 2015 Khanna Vision ... the art web portal focussed on keratoconus eye disease ... relentless progressive disease has its onset in the teenage years. ... The cornea or the front clear part of the eye ... pressure in the eye. It results in poor vision which ...
(Date:5/27/2015)... Wis. (PRWEB) May 27, 2015 “We ... Julie Schuller, MD, executive vice president and vice president ... this grant makes possible allows us to provide comprehensive ... of our community.” , SSCHC provides clinical care and ... over 35,000 people in 2014, many of whom took ...
(Date:5/27/2015)... May 27, 2015 Hundreds of ... behalf of individuals who allegedly suffered gynecomastia (male ... use of the antipsychotic drug continue to move ... in Pennsylvania’s Philadelphia Court of Common Pleas. According ... its bellwether trial program, as the third trial ...
(Date:5/27/2015)... 27, 2015 With the launch of ... robust Network Management Module (NMM) tool, monitoring provider-network adequacy ... issue of Atlantic Information Services, Inc.’s (AIS) Medicare Advantage ... tool, as well as analysis from industry experts on ... changes coming to the NMM were announced at CMS’s ...
(Date:5/27/2015)... 27, 2015 In today's healthcare landscape, ... it can be challenging for doctors and hospitals to ... treatments. , Austin-based HealthTronics, Inc. is ... mobile medical therapies for clinically sophisticated applications. The company ... acquisition of Laser Ventures, Inc ., a mobile ...
Breaking Medicine News(10 mins):Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Sixteenth Street Community Health Centers To Expand Primary Care and Behavioral Health Services Through $1 Million Grant From Aurora's Better Together Fund 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3
... , PURCHASE, N.Y., Aug. 12 ... on a preliminary and unaudited basis it expects revenues for the ... that it expects to incur a net loss for the quarter ... for intangible assets. Operating profit for the fiscal year is ...
... Finding runs counter to standard advice doctors have given for ... can help prevent flare-ups of lymphedema, a painful swelling of ... research shows. , The finding runs counter to what women ... stressing the arm during strength training or other exercise because ...
... brain abnormalities may cause learning problems, study finds, , ... with epilepsy should have their language, memory, learning and ... for problems, say U.S. researchers. , The recommendation stems ... IQ of at least 70 who had experienced their ...
... , , , ... ,Honorary Ambassador, By Project Lifesaver International , , ... Lifesaver International, a non-profit organization that helps rescue citizens that ... honored Erik Estrada at a ceremony Sunday in Lynchburg, Virginia. ...
... , , CLEVELAND, Aug. 12 ... Shannon Fogarty Jerse to its legal department. Jerse will serve as ... role as Deputy General Counsel for the health system. , ... the breadth of legal expertise that Shannon brings to this new ...
... , NEW YORK, Aug. 12 Gloria ... Ogilvy Healthworld North America, have been appointed Joint Worldwide CEOs of ... , , In making the announcement, Mr. Young ... are also very complementary individuals. Their joint mandate is to ...
Cached Medicine News:Health News:Nutrition 21 Announces Preliminary Fourth Quarter Financial Update Also Announces Negotiations on Notes due August 25, 2009 2Health News:Weight Lifting Can Ease Arm Swelling in Breast Cancer Survivors 2Health News:Weight Lifting Can Ease Arm Swelling in Breast Cancer Survivors 3Health News:Experts Urge Cognitive Testing of Kids With Epilepsy 2Health News:Erik Estrada Accepts Honorary Appointment from Project Lifesaver International 2Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 2Health News:Sisters of Charity Health System Welcomes Shannon Fogarty Jerse as Deputy General Counsel 3Health News:Joint Worldwide CEO's of Ogilvy Healthworld Named 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: